EGFR and colorectal cancer: Upon re-treatment with saracatinib, Sox2-upregulated cells formed larger spheroids under GF-supplemented conditions compared with wild-type cells.<h4>Conclusions</h4>Saracatinib exerts anti-cancer effects in colorectal cancer cells by downregulating MAPKs, EGFR, and CSC-associated markers.